Cell Metab 2016;24:15-30.ArticlePubMed REFERENCES PubReader ePub Link Cite this Article Cite this Article Close Download Citation Close XML Download Figure Related articles Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents Prognostic Impact of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Coronary Ischemia: A Retrospective Cohort Study New Users of Sodium-Glucose Cotransporter 2 Inhibitors Are at Low Risk of Prostate Cancer: A Nationwide Cohort Study Anti-Senescence Effect of Inhibiting Sodium-Glucose Cotransporter 2 and -Glucosidase in a Type 2 Diabetes Mellitus Animal Model Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus Fig
Zepbound (tirzepatide): Manufactured by Eli Lilly, FDA-approved for chronic weight management
Their ability to delay gastric emptying further contributes to reduced hunger, which explains their growing use in weight management therapies
LysoPC is the most abundant LysoPL in human plasma, and it is involved in vascular endothelial expansion, cellular immune response, and insulin secretion
62,63 We were also unable to evaluate any heterogeneity of effects, such as whether semaglutide presents a greater risk for NAION among patients with anatomic predisposition or more severe diabetes (eg, by duration or hemoglobin A 1c level) or whether risk differs for patients who take semaglutide for obesity
)
